| 1. |
范仰钢, 胡尊玲, 姚国忠. 类风湿性关节炎患者肺部真菌感染的危险因素分析. 中华医院感染学杂志, 2014, 24(6): 1389-1391.
|
| 2. |
谢岩, 林翊萍. 类风湿关节炎与感染相关研究进展. 中国免疫学杂志. (2020-08-23)[2020-10-28]. http://kns.cnki.net/kcms/detail/22.1126.R.20200821.1944.002.html.
|
| 3. |
Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken), 2014, 66(7): 990-997.
|
| 4. |
Liao TL, Chen YM, Chen DY. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect, 2016, 22(9): 815. e1-815. e3.
|
| 5. |
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev, 2000, 13(2): 236-301.
|
| 6. |
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel), 2019, 5(1): 26.
|
| 7. |
Petrikkos G, Skiada A, Drogari-Apiranthitou M. Epidemiology of mucormycosis in Europe. Clin Microbiol Infect, 2014, 20(Suppl 6): 67-73.
|
| 8. |
Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis, 2012, 54(Suppl 1): S23-S34.
|
| 9. |
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis, 2019, 19(12): e405-e421.
|
| 10. |
Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect, 2014, 20(Suppl 3): 5-26.
|
| 11. |
刘涵, 廖勇, 杨蓉娅, 等. 2013欧洲毛霉病临床诊疗指南解读. 实用皮肤病学杂志, 2014(3): 201-203.
|
| 12. |
Ruiz Camps I, Salavert Lletí M. The treatment of mucormycosis (zygomycosis) in the 21st century. Rev Iberoam Micol, 2018, 35(4): 217-221.
|
| 13. |
郭思远, 尹青琴, 秦强, 等. 影响毛霉菌病患者病死率相关因素的Meta分析. 临床和实验医学杂志, 2019, 18(22): 2432-2435.
|
1/5
WeChat